Drugs influencing acid base balance and bicarbonate concentration readings

References

• Notice technique de dosage bicarbonates. Plaques VITROS Chemistry Products ECO2 [Internet]. Available from: http://www.laboratoire-duquaivalliere.fr/notices%20analyses/ECO2_MP2-89_FR_I.pdf
   Google Scholar
• Notice dosage bicarbonates. Cobas substrate Oriapole. Roche. 2007.
   Google Scholar
• Mokhlesi B, Saager L, Kaw R. Q: should we routinely screen for hypercapnia in sleep apnea patients before elective noncardiac surgery? Cleve Clin J Med. 2010;77:60–61.
   PubMed Web of Science ®Google Scholar
• Nowbar S, Burkart KM, Gonzales R, et al. Obesity-associated hypoventilation in hospitalized patients: prevalence, effects, and outcome. Am J Med. 2004;116:1–7.
   PubMed Web of Science ®Google Scholar
• Borel J-C, Burel A-L, Monneret D, et al. Obesity hypoventilation syndrome: from sleep-disordered breathing to systemic comorbidities and the need to offer combined treatment strategies. Respirol Carlton Vic. 2012;17:601–610.
   PubMed Web of Science ®Google Scholar
• Priou P, Hamel J-F, Person C, et al. Long-term outcome of noninvasive positive pressure ventilation for obesity hypoventilation syndrome. Chest. 2010;138:84–90.
   PubMed Web of Science ®Google Scholar
• Borel J-C, Burel B, Tamisier R, et al. Comorbidities and mortality in hypercapnic obese under domiciliary noninvasive ventilation. PloS One. 2013;8:e52006.
   PubMed Web of Science ®Google Scholar
• Castro-Añón O, Pérez De Llano LA, De La Fuente Sánchez S, et al. Obesity-hypoventilation syndrome: increased risk of death over sleep apnea syndrome. PloS One. 2015;10:e0117808.
   Web of Science ®Google Scholar
• Pépin J-L, Borel J-C, Janssens J-P. Obesity hypoventilation syndrome: an underdiagnosed and undertreated condition. Am J Respir Crit Care Med. 2012;186:1205–1207.
   PubMed Web of Science ®Google Scholar
• Masa JF, Corral J, Alonso ML, et al. Efficacy of different treatment alternatives for obesity hypoventilation syndrome. Pickwick study. Am J Respir Crit Care Med. 2015;192:86‑95.
   PubMed Web of Science ®Google Scholar
• Borel J-C, Tamisier R, Gonzalez-Bermejo J, et al. Noninvasive ventilation in mild obesity hypoventilation syndrome: a randomized controlled trial. Chest. 2012;141:692–702.
   PubMed Web of Science ®Google Scholar
• Mokhlesi B, Tulaimat A, Faibussowitsch I, et al. Obesity hypoventilation syndrome: prevalence and predictors in patients with obstructive sleep apnea. Sleep Breath Schlaf Atm. 2007;11:117–124.
   PubMed Web of Science ®Google Scholar
• Manuel ARG, Hart N, Stradling JR. Is a raised bicarbonate, without hypercapnia, part of the physiologic spectrum of obesity-related hypoventilation? Chest. 2015;147:362–368.
   PubMed Web of Science ®Google Scholar
• Jennum P, Ibsen R, Kjellberg J. Morbidity prior to a diagnosis of sleep-disordered breathing: a controlled national study. J Clin Sleep Med JCSM Off Publ Am Acad Sleep Med. 2013;9:103–108.
   PubMed Web of Science ®Google Scholar
• Berend K, De Vries APJ, Gans ROB. Physiological approach to assessment of acid-base disturbances. N Engl J Med. 2014;371:1434–1445.
   PubMed Web of Science ®Google Scholar
• Palmer BF, Clegg DJ. Electrolyte and acid-base in patients with diabetes mellitus. N Engl J Med. 2015;373:548–559.
   PubMed Web of Science ®Google Scholar
• Renda F, Mura P, Finco G, et al. Metformin-associated lactic acidosis requiring hospitalization. A national 10 year survey and a systematic literature review. Eur Rev Med Pharmacol Sci. 2013;17(Suppl 1):45–49.
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Lipska KJ, Mayo H, et al. Metformin in patients with type 2 diabetes and kidney disease: a systematic review. Jama. 2014;312:2668–2675.
   PubMed Web of Science ®Google Scholar
• Richy FF, Sabidó-Espin M, Guedes S, et al. Incidence of lactic acidosis in patients with type 2 diabetes with and without renal impairment treated with metformin: a retrospective cohort study. Diabetes Care. 2014;37:2291–2295.
   PubMed Web of Science ®Google Scholar
• Shiber JR. Lactic acidosis caused by nucleoside analogues. Am J Emerg Med. 2005;23:582–583.
   PubMed Web of Science ®Google Scholar
• Fichtenbaum CJ. Metabolic abnormalities associated with HIV infection and antiretroviral therapy. Curr Infect Dis Rep. 2009;11:84–92.
   PubMedGoogle Scholar
• Margolis AM, Heverling H, Pham PA, et al. A review of the toxicity of HIV medications. J Med Toxicol Off J Am Coll Med Toxicol. 2014;10:26–39.
   PubMedGoogle Scholar
• Falcó V, Crespo M, Ribera E. Lactic acidosis related to nucleoside therapy in HIV-infected patients. Expert Opin Pharmacother. 2003;4:1321–1329.
   PubMed Web of Science ®Google Scholar
• Wester CW, Okezie OA, Thomas AM, et al. Higher-than-expected rates of lactic acidosis among highly active antiretroviral therapy-treated women in Botswana: preliminary results from a large randomized clinical trial. J Acquir Immune Defic Syndr 1999. 2007;46:318–22.
   PubMed Web of Science ®Google Scholar
• Giola M, Basilico C, Grossi P. Fatal lactic acidosis associated with tenofovir and abacavir. Int J Infect Dis IJID Off Publ Int Soc Infect Dis. 2005;9:228–229.
   PubMed Web of Science ®Google Scholar
• Dragovic G, Jevtovic D. The role of nucleoside reverse transcriptase inhibitors usage in the incidence of hyperlactatemia and lactic acidosis in HIV/AIDS patients. Biomed Pharmacother Bioméd Pharmacothérapie. 2012;66:308–311.
   PubMed Web of Science ®Google Scholar
• Rivas P, Polo J, De Górgolas M, et al. Drug points: fatal lactic acidosis associated with tenofovir. Bmj. 2003;327:711.
   PubMed Web of Science ®Google Scholar
• Jin J-L, Hu P, Lu J-H, et al. Lactic acidosis during telbivudine treatment for HBV: a case report and literature review. World J Gastroenterol WJG. 2013;19:5575–5580.
   PubMed Web of Science ®Google Scholar
• Kritharides L, Fassett R, Singh B. Paracetamol-associated coma, metabolic acidosis, renal and hepatic failure. Intensive Care Med. 1988;14:439–440.
   PubMed Web of Science ®Google Scholar
• Shah AD, Wood DM, Dargan PI. Understanding lactic acidosis in paracetamol (acetaminophen) poisoning. Br J Clin Pharmacol. 2011;71:20–28.
   PubMed Web of Science ®Google Scholar
• Liss DB, Paden MS, Schwarz ES, et al. What is the clinical significance of 5-oxoproline (pyroglutamic acid) in high anion gap metabolic acidosis following paracetamol (acetaminophen) exposure? Clin Toxicol Phila Pa. 2013;51:817–827.
   PubMed Web of Science ®Google Scholar
• O’Brien LMN, Hooper M, Flemmer M, et al. Chronic acetaminophen ingestion resulting in severe anion gap metabolic acidosis secondary to 5-oxoproline accumulation: an under diagnosed phenomenon. BMJ Case Rep. 2012. pii: bcrbcr0320126020. doi:10.1136/bcr.03.2012.6020
   Google Scholar
• Lee CH, Kim G-H. Electrolyte and acid-base disturbances induced by clacineurin inhibitors. Electrolyte Blood Press E BP. 2007;5:126–130.
   PubMedGoogle Scholar
• Oliveira JLD, Silva Júnior GBD, Abreu KLSD, et al. Lithium nephrotoxicity. Rev Assoc Médica Bras 1992. 2010;56:600–606.
   Google Scholar
• Inoue T, Kira R, Kaku Y, et al. Renal tubular acidosis associated with zonisamide therapy. Epilepsia. 2000;41:1642–1644.
   PubMed Web of Science ®Google Scholar
• Eskandari D, Zou D, Karimi M, et al. Zonisamide reduces obstructive sleep apnoea: a randomised placebo-controlled study. Eur Respir J. 2014;44:140–149.
   PubMed Web of Science ®Google Scholar
• Henger A, Tutt P, Riesen WF, et al. Acid-base and endocrine effects of aldosterone and angiotensin II inhibition in metabolic acidosis in human patients. J Lab Clin Med. 2000;136:379–389.
   PubMed Web of Science ®Google Scholar
• Sakemi T, Ohchi N, Sanai T, et al. Captopril-induced metabolic acidosis with hyperkalemia. Am J Nephrol. 1988;8:245–248.
   PubMed Web of Science ®Google Scholar
• Hall AM, Bass P, Unwin RJ. Drug-induced renal Fanconi syndrome. QJM Mon J Assoc Physicians. 2014;107:261–269.
   PubMed Web of Science ®Google Scholar
• Sarafidis PA, Georgianos PI, Lasaridis AN. Diuretics in clinical practice. Part II: electrolyte and acid-base disorders complicating diuretic therapy. Expert Opin Drug Saf. 2010;9:259–273.
   PubMed Web of Science ®Google Scholar
• Heller I, Halevy J, Cohen S, et al. Significant metabolic acidosis induced by acetazolamide. Not a rare complication. Arch Intern Med. 1985;145:1815–1817.
   PubMed Web of Science ®Google Scholar
• Chapron DJ, Gomolin IH, Sweeney KR. Acetazolamide blood concentrations are excessive in the elderly: propensity for acidosis and relationship to renal function. J Clin Pharmacol. 1989;29:348–353.
   PubMed Web of Science ®Google Scholar
• Leem AY, Kim HS, Yoo BW, et al. Ifosfamide-induced Fanconi syndrome with diabetes insipidus. Korean J Intern Med. 2014;29:246–249.
   PubMed Web of Science ®Google Scholar
• Lehrich RW, Moll S, Luft FC. Evaluating a critically ill patient with metabolic acidosis: the ifosfamide paradigm. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 1999;14:226–230.
   PubMed Web of Science ®Google Scholar
• Negro A, Grasselli C, Galli P. Oxaliplatin-induced proximal renal tubular acidosis. Intern Emerg Med. 2010;5:267–268.
   PubMed Web of Science ®Google Scholar
• Shiraishi Y, Nagai J, Murakami T, et al. Effect of cisplatin on H+ transport by H+ -ATPase and Na+/H+ exchanger in rat renal brush-border membrane. Life Sci. 2000;67:1047–1058.
   PubMed Web of Science ®Google Scholar
• Brivet FG, Slama A, Prat D, et al. Carboplatin: a new cause of severe type B lactic acidosis secondary to mitochondrial DNA damage. Am J Emerg Med. 2011;29:842.e5–7.
   PubMed Web of Science ®Google Scholar
• Kintzel PE. Anticancer drug-induced kidney disorders. Drug Saf. 2001;24:19–38.
   PubMed Web of Science ®Google Scholar
• Shaikh A, Wiisanen ME, Gunderson HD, et al. Acquired Fanconi syndrome after treatment with capecitabine, irinotecan, and bevacizumab. Ann Pharmacother. 2009;43:1370–1373.
   PubMed Web of Science ®Google Scholar
• Nelson M, Azwa A, Sokwala A, et al. Fanconi syndrome and lactic acidosis associated with stavudine and lamivudine therapy. AIDS Lond Engl. 2008;22:1374–1376.
   PubMed Web of Science ®Google Scholar
• Chaudhry N, Patidar Y, Puri V. Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes unveiled by valproate. J Pediatr Neurosci. 2013;8:135–137.
   PubMedGoogle Scholar
• Nanau RM, Neuman MG. Adverse drug reactions induced by valproic acid. Clin Biochem. 2013;46:1323–38.
   PubMed Web of Science ®Google Scholar
• Dell’Orto VG, Bianchetti MG, Brazzola P. Hyperchloraemic metabolic acidosis induced by the iron chelator deferasirox: a case report and review of the literature. J Clin Pharm Ther. 2013;38:526–527.
   PubMed Web of Science ®Google Scholar
• Torimoto K, Okada Y, Arao T, et al. A case of zoledronate-induced tubulointerstitial nephritis with Fanconi syndrome. Endocr J. 2012;59:1051–1056.
   PubMed Web of Science ®Google Scholar
• Szeto CC, Chow KM. Nephrotoxicity related to new therapeutic compounds. Ren Fail. 2005;27:329–333.
   PubMed Web of Science ®Google Scholar
• Evans SJ, Webb D, Lawson TM, et al. Renal tubular acidosis associated with leflunomide. Rheumatol Oxf Engl. 2007;46:1040.
   PubMed Web of Science ®Google Scholar
• Fernández-de Orueta L, Esteban-Fernández J, Aichner HFJ, et al. Topiramate-induced metabolic acidosis: a case study. Nefrol Publ Of Soc Esp Nefrol. 2012;32:403–404.
   Google Scholar
• Mirza N, Marson AG, Pirmohamed M. Effect of topiramate on acid-base balance: extent, mechanism and effects. Br J Clin Pharmacol. 2009;68:655–661.
   PubMed Web of Science ®Google Scholar
• Kim S, Joo KW. Electrolyte and acid-base disturbances associated with non-steroidal anti-inflammatory drugs. Electrolyte Blood Press E BP. 2007;5:116–125.
   PubMedGoogle Scholar
• Patel MC. Trimethoprim related hyperkalaemia in a patient with renal tubular acidosis type 4. Acute Med. 2009;8:117–118.
   PubMedGoogle Scholar
• Clouston WM, Lloyd HM. Cholestyramine induced hyperchloremic metabolic acidosis. Aust N Z J Med. 1985;15:271.
   PubMedGoogle Scholar
• Eaves ER, Korman MG. Cholestyramine induced hyperchloremic metabolic acidosis. Aust N Z J Med. 1984;14:670–672.
   PubMedGoogle Scholar
• Scheel PJ, Whelton A, Rossiter K, et al. Cholestyramine-induced hyperchloremic metabolic acidosis. J Clin Pharmacol. 1992;32:536–538.
   PubMed Web of Science ®Google Scholar
• Patel AM, Adeseun GA, Goldfarb S. Calcium-alkali syndrome in the modern era. Nutrients. 2013;5:4880–4893.
   PubMed Web of Science ®Google Scholar
• Kitterer D, Schwab M, Alscher MD, et al. Drug-induced acid-base disorders. Pediatr Nephrol Berl Ger. 2015;30:1407–1423.
   PubMed Web of Science ®Google Scholar
• Müller-Lissner S. Side effects of laxatives. Z Für Gastroenterol. 1992;30:418–427.
   PubMed Web of Science ®Google Scholar
• Burns A, Brown TM, Semple P. Extreme metabolic alkalosis with fludrocortisone therapy. Postgrad Med J. 1983;59:506–507.
   PubMed Web of Science ®Google Scholar
• Escanero JF, Elosegui LM, Cordova A, et al. Calcitonin and metabolic alkalosis. Biomed Pharmacother Bioméd Pharmacothérapie. 1991;45:307–309.
   PubMed Web of Science ®Google Scholar
• Shetty AK, Rogers NL, Mannick EE, et al. Syndrome of hypokalemic metabolic alkalosis and hypomagnesemia associated with gentamicin therapy: case reports. Clin Pediatr (Phila). 2000;39:529–533.
   PubMed Web of Science ®Google Scholar
• Fenves AZ, Kirkpatrick HM, Patel VV, et al. Increased anion gap metabolic acidosis as a result of 5-oxoproline (pyroglutamic acid): a role for acetaminophen. Clin J Am Soc Nephrol CJASN. 2006;1:441–447.
   PubMed Web of Science ®Google Scholar
• Peter JV, Rogers N, Murty S, et al. An unusual cause of severe metabolic acidosis. Med J Aust. 2006;185:223–225.
   PubMed Web of Science ®Google Scholar
• Rolleman EJ, Hoorn EJ, Didden P, et al. Guilty as charged: unmeasured urinary anions in a case of pyroglutamic acidosis. Neth J Med. 2008;66:351–353.
   PubMed Web of Science ®Google Scholar
• Luyasu S, Wamelink MMC, Galanti L, et al. Pyroglutamic acid-induced metabolic acidosis: a case report. Acta Clin Belg. 2014;69:221–223.
   PubMed Web of Science ®Google Scholar
• Brunner FP, Frick PG. Hypokalaemia, metabolic alkalosis, and hypernatraemia due to “massive” sodium penicillin therapy. Br Med J. 1968;4:550–552.
   PubMed Web of Science ®Google Scholar
• Apodaca AA, Rakita RM. Linezolid-induced lactic acidosis. N Engl J Med. 2003;348:86–87.
   PubMed Web of Science ®Google Scholar
• Palenzuela L, Hahn NM, Nelson RP, et al. Does linezolid cause lactic acidosis by inhibiting mitochondrial protein synthesis? Clin Infect Dis Off Publ Infect Dis Soc Am. 2005;40:e113–e116.
   Web of Science ®Google Scholar
• Su E, Crowley K, Carcillo JA, et al. Linezolid and lactic acidosis: a role for lactate monitoring with long-term linezolid use in children. Pediatr Infect Dis J. 2011;30:804–806.
   PubMed Web of Science ®Google Scholar
• Sanford WG, Rasch JR, Stonehill RB. A therapeutic dilemma. The treatment of disseminated coccidioidomycosis with amphotericin B. Ann Intern Med. 1962;56:553–563.
   PubMed Web of Science ®Google Scholar
• Navarro JF, Quereda C, Moreno A, et al. Renal tubular acidosis following treatment with foscarnet. AIDS Lond Engl. 1995;9:1389–1390.
   Google Scholar
• Kleyman TR, Roberts C, Ling BN. A mechanism for pentamidine-induced hyperkalemia: inhibition of distal nephron sodium transport. Ann Intern Med. 1995;122:103–106.
   PubMed Web of Science ®Google Scholar
• Palen BN, Swenson ER. Is a raised eucapnic blood bicarbonate value a Bellwether of preclinical obesity hypoventilation syndrome? Chest. 2015;147:282–284.
   PubMed Web of Science ®Google Scholar
• Tulaimat A, Littleton S. Defining obesity hypoventilation syndrome. Thorax. 2014;69:491.
   PubMed Web of Science ®Google Scholar